15 assets in Malignant Peripheral Nerve Sheath Tumor

Therapeutic assets addressing Malignant Peripheral Nerve Sheath Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Malignant Peripheral Nerve Sheath Tumor	St. Jude Children's Research Hospital	P2	B (60)
Fludarabine Malignant Peripheral Nerve Sheath Tumor	St. Jude Children's Research Hospital	P2	B (59)
Pembrolizumab Malignant Peripheral Nerve Sheath Tumor	Seattle Children's Hospital	P1/2	CCC (54)
Ipilimumab Malignant Peripheral Nerve Sheath Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Malignant Peripheral Nerve Sheath Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selinexor Malignant Peripheral Nerve Sheath Tumor	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Telaglenastat Malignant Peripheral Nerve Sheath Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Apg 115 Malignant Peripheral Nerve Sheath Tumor	Ascentage Pharma Group Inc.	P1/2	CCC (48)
b7-h3 car t cells Malignant Peripheral Nerve Sheath Tumor	St. Jude Children's Research Hospital	P1	CC (43)
Mesna Malignant Peripheral Nerve Sheath Tumor	St. Jude Children's Research Hospital	P1	CC (43)
Metarrestin Malignant Peripheral Nerve Sheath Tumor	National Cancer Institute (NCI)	P1	CC (43)
Mrtx1719 Malignant Peripheral Nerve Sheath Tumor	Bristol-Myers Squibb	P1	CC (43)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Malignant Peripheral Nerve Sheath Tumor	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt Malignant Peripheral Nerve Sheath Tumor	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Malignant Peripheral Nerve Sheath Tumor	Seattle Children's Hospital	P1	CC (43)